The most clinically studied peptides in body composition research are GLP-1 receptor agonists — synthetic analogs of the natural glucagon-like peptide-1 hormone that have demonstrated significant fat mass changes in large-scale Phase 3 trials: semaglutide at 14.9% average body weight change in STEP 1 (n=1,961), tirzepatide at up to 22.5% in SURMOUNT-1 (n=2,539), and retatrutide at approximately 24% at 48 weeks in Phase 2 (n=338). Understanding how these compounds work biologically — and how they compare to non-GLP-1 metabolic research peptides — is the focus of this overview.
Peptides for fat loss research span several mechanistic categories: GLP-1 receptor agonists (operating on appetite regulation and gastric emptying), GIP/GLP-1 dual agonists (broader incretin coverage), triple agonists (adding glucagon axis modulation), and non-incretin metabolic compounds like AOD-9604 and HGH Fragment 176-191. This article reviews each category and the published evidence behind them.
Pure Grade Labs supplies GLP-1 analogs — including Semaglutide 10MG, Tirzepatide 10MG, and Retatrutide 10MG — as research chemicals for in vitro laboratory use only. All are prescription-only medications in many jurisdictions and are not supplied for human consumption.
Key Takeaways
- GLP-1 (Glucagon-Like Peptide-1) has a natural plasma half-life of approximately 7 minutes — synthetic analogs extend this to days or weeks via albumin binding or fatty acid conjugation
- Semaglutide (STEP 1 trial, 2021, NEJM): 14.9% average body weight change vs 2.4% placebo in 68-week Phase 3 trial (n=1,961)
- Tirzepatide (SURMOUNT-1 trial, 2022, NEJM): up to 22.5% average body weight reduction at 15mg/week, 72 weeks (n=2,539)
- Retatrutide (Phase 2, 2023, NEJM): triple agonism (GLP-1/GIP/glucagon) demonstrated approximately 24.2% weight reduction at 48 weeks at highest dose
- Non-GLP-1 metabolic peptides — including AOD-9604 — operate through distinct mechanisms (beta-3 adrenergic activation, selective lipolysis) with separate clinical evidence trails
Research-Grade GLP-1 Compounds — HPLC Verified
Semaglutide, Tirzepatide, Retatrutide — batch COA included. For research use only.
Browse Metabolic Research Compounds →The Biology of GLP-1: Why Synthetic Analogs Were Developed
Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone produced by L-cells in the intestinal mucosa in response to nutrient ingestion. Its primary physiological roles are: stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and signalling satiety via central nervous system GLP-1 receptors in the hypothalamus and brainstem.
The problem with native GLP-1 as a research and therapeutic tool is its extremely short half-life: approximately 7 minutes in plasma before degradation by dipeptidyl peptidase-4 (DPP-4). The entire pharmacological development effort behind semaglutide, tirzepatide, and retatrutide has been directed at solving this single pharmacokinetic problem — extending half-life to allow once-weekly subcutaneous administration while preserving or enhancing receptor binding affinity.
How GLP-1 Analogs Achieve Extended Half-Life
Semaglutide achieves its extended half-life (~7 days) through fatty acid conjugation to a C18 fatty diacid chain via a linker, enabling reversible albumin binding. This protects the molecule from DPP-4 degradation and renal clearance — the result is a compound that maintains effective receptor engagement for a full week from a single subcutaneous dose.
Tirzepatide extends this further by adding GIP receptor (glucose-dependent insulinotropic polypeptide receptor) agonism alongside GLP-1 receptor engagement — a dual agonist approach that activates two incretin pathways simultaneously. The GIP receptor component is thought to contribute additional effects on adipogenesis, fat oxidation, and energy expenditure beyond those achievable via GLP-1 receptor alone [2].
The development of semaglutide began with a fundamental pharmacology question: the natural GLP-1 molecule demonstrated exactly the biology researchers wanted, but DPP-4 destroyed it before it could be useful. The albumin-binding solution — a fatty acid chain long enough to bind albumin reversibly, protecting the peptide without blocking its receptor — transformed a 7-minute molecule into a 7-day one. The resulting compound, tested in the STEP trial programme across more than 4,500 participants, demonstrated a 14.9% average body weight change versus placebo in 68 weeks. The mechanism was already known. The challenge was always the half-life.
Semaglutide Research: STEP Trial Programme
Semaglutide at 2.4mg weekly (the dose studied for body composition outcomes, distinct from the 0.5–1mg diabetic dosing) was evaluated across the STEP (Semaglutide Treatment Effect in People with Obesity) trial programme — the largest GLP-1 body composition trial series conducted to date.
STEP 1 (Wilding et al., 2021, NEJM, n=1,961): 68-week randomised controlled trial in adults with BMI ≥30 (or ≥27 with weight-related comorbidity). Semaglutide 2.4mg/week produced mean body weight change of −14.9% versus −2.4% with placebo. 86.4% of semaglutide participants achieved ≥5% weight reduction versus 31.5% of placebo participants [1].
STEP 4 (Rubino et al., 2021, JAMA): Participants who achieved weight loss with semaglutide were randomised to continue or switch to placebo. The continued-treatment group maintained −17.4% total weight reduction; the switched-to-placebo group regained to −5% — demonstrating that the body composition effects are dependent on ongoing GLP-1 receptor engagement, not a permanent metabolic reset.
The mechanism behind the body composition outcomes in semaglutide research is primarily central: GLP-1 receptors in the hypothalamic arcuate nucleus and nucleus accumbens regulate appetite and reward-driven feeding behaviour. Semaglutide's extended engagement of these receptors produces sustained reductions in caloric intake without the rebound hyperphagia seen with caloric restriction alone — which is what differentiates it mechanistically from dietary intervention models.
Tirzepatide Research: Dual GLP-1/GIP Agonism and SURMOUNT-1
Tirzepatide is a dual GLP-1/GIP receptor agonist — the first approved incretin compound to target both receptor families simultaneously. GIP receptors are expressed in adipose tissue, where their activation has been shown to modulate adipogenesis and fat cell turnover; in combination with GLP-1 receptor-mediated appetite suppression and gastric emptying delay, the dual mechanism produces additive body composition effects compared to GLP-1 alone.
SURMOUNT-1 (Jastreboff et al., 2022, NEJM, n=2,539): 72-week randomised controlled trial. At the 15mg/week dose, participants achieved a mean body weight reduction of 22.5% — the largest average reduction in any Phase 3 metabolic research trial to date at the time of publication. At 5mg and 10mg doses, mean reductions were 15.0% and 19.5% respectively [2]. All doses demonstrated significantly superior outcomes to placebo (−2.5%).
The superior body composition outcomes of tirzepatide versus semaglutide in head-to-head research have been attributed primarily to the additive GIP component. GIP receptor activation in white adipose tissue promotes thermogenic browning signals, while GLP-1 receptor activation drives central appetite suppression — together, the two pathways address both caloric intake (central) and caloric expenditure/storage (peripheral) dimensions of energy balance simultaneously.
Source Tirzepatide & Semaglutide for Research
Batch-tested. HPLC-verified. COA available. Prescription-only — for laboratory research use only.
View Research Compounds →Retatrutide Research: Triple Agonism (GLP-1/GIP/Glucagon)
Retatrutide represents the next mechanistic step in incretin pharmacology: a triple agonist engaging GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor agonism — counterintuitive given glucagon's hyperglycaemic reputation — is justified by glucagon's role in hepatic fat oxidation and energy expenditure when combined with GLP-1 (which prevents the glycaemic rise that glucagon alone would cause).
Phase 2 Trial (Jastreboff et al., 2023, NEJM, n=338): 48-week dose-ranging study at 1mg, 4mg, 8mg, and 12mg weekly doses. At the highest dose (12mg), participants demonstrated approximately 24.2% average body weight reduction at 48 weeks — suggesting a dose-response relationship with substantially greater body composition effects than either GLP-1 monotherapy or dual GLP-1/GIP agonism at equivalent timepoints [3]. Phase 3 trials are ongoing.
The glucagon receptor component is thought to drive hepatic fat oxidation and brown adipose tissue thermogenesis — adding an energy expenditure dimension to the appetite/intake reduction achieved by GLP-1 and GIP. This triple-pathway approach makes retatrutide the most mechanistically comprehensive metabolic research compound currently in clinical trials.
Researchers designing the retatrutide Phase 2 protocol faced a challenge that had limited previous triple agonist attempts: glucagon receptor activation raises blood glucose — exactly what you want to avoid in a metabolic compound. The solution was to calibrate the glucagon component at a level that activates hepatic fat oxidation without overwhelming GLP-1's insulin-stimulating activity. The Phase 2 results showed the balance worked: at 12mg weekly, participants demonstrated 24.2% body weight reduction at 48 weeks with no clinically significant hyperglycaemia signals beyond the established GLP-1/GIP profile. The mechanistic hypothesis about glucagon-driven fat oxidation appeared to hold in human subjects.
Non-GLP-1 Metabolic Research Peptides: AOD-9604 and HGH Fragment 176-191
Not all metabolic peptides in body composition research operate through the incretin system. AOD-9604 and HGH Fragment 176-191 represent an entirely distinct mechanistic category — operating through selective beta-3 adrenergic receptor activation in adipose tissue, independent of GLP-1, GIP, or glucagon pathways.
AOD-9604: Beta-3 Adrenergic Mechanism
AOD-9604 is a 16-amino acid synthetic peptide derived from the C-terminal region of human growth hormone (hGH), specifically designed to isolate the lipolytic properties of hGH without triggering growth hormone receptor activation or IGF-1 elevation. Research shows AOD-9604 selectively activates beta-3 adrenergic receptors in adipose tissue — which means it targets the receptor subtype responsible for fat cell lipolysis while avoiding the anabolic (growth-stimulating) and diabetogenic effects associated with full-length HGH administration.
Phase IIb (METAOD005): Randomised controlled trial testing doses of 1mg, 5mg, 10mg, 20mg, and 30mg daily versus placebo. The 1mg daily dose demonstrated statistically significant fat mass reduction versus placebo over 12 weeks, without loss of lean tissue. Higher doses showed no additional benefit — suggesting a ceiling effect in beta-3 adrenergic activation. Importantly, no significant IGF-1 elevation was observed at any tested dose, confirming the mechanistic selectivity that distinguishes AOD-9604 from parent hGH.
HGH Fragment 176-191: Selective C-Terminal Fragment
HGH Fragment 176-191 (the C-terminal fragment of human growth hormone) shares similar mechanistic territory to AOD-9604 — selective lipolytic activity without receptor activation for the full GH receptor complex. Published research on the fragment demonstrates selective activation of fat cell catabolism pathways while leaving IGF-1 secretion unaffected, making it a research compound of interest for studying body composition without the full endocrine profile of growth hormone.
Note: HGH Fragment 176-191 sits in a regulatory grey area in the UK context. Pure Grade Labs supplies it as a research chemical only, for in vitro laboratory use. For research purposes only. Not for human consumption. No medical claims are made.
Metabolic Peptide Research Comparison
| Compound | Receptor Target | Key Trial Data | Compliance Status (UK) |
|---|---|---|---|
| Semaglutide | GLP-1R agonist | −14.9% body weight (STEP 1, 68wk) | 🔴 POM — Research only |
| Tirzepatide | GLP-1R + GIPR dual agonist | −22.5% body weight (SURMOUNT-1, 72wk) | 🔴 POM — Research only |
| Retatrutide | GLP-1R + GIPR + GlucagonR triple agonist | ~24.2% body weight (Phase 2, 48wk) | 🔴 POM — Research only |
| AOD-9604 | β3-adrenergic receptor (selective) | Significant fat mass reduction at 1mg (METAOD005 Phase IIb); no IGF-1 elevation | ✅ Safe — Research only |
| HGH Fragment 176-191 | Selective lipolytic (C-terminal hGH fragment) | Preclinical lipolysis without IGF-1 elevation; limited clinical data | ⚠️ Grey area — Research only. No medical claims. |
A researcher reviewing metabolic compounds for a body composition model needed to distinguish between two fundamentally different mechanisms: central appetite regulation (the GLP-1 receptor pathway, driving reduced caloric intake) and peripheral fat cell catabolism (the beta-3 adrenergic pathway, driving increased lipolysis). Selecting the right compound depends entirely on which part of energy balance the research model is designed to investigate. GLP-1 analogs address the intake side; AOD-9604 and HGH Fragment address the expenditure/storage side. In multi-mechanism research models, they can be studied in parallel because their receptor targets do not overlap.
Full Metabolic Research Range — AOD-9604, GLP-1 Analogs & More
HPLC-verified. Batch COA with every order. UK warehouse. Research use only.
Get Pure Grade Research Compounds →Frequently Asked Questions
What is the difference between semaglutide and tirzepatide in research?
Semaglutide is a GLP-1 receptor monoagonist — it engages only the GLP-1 receptor. Tirzepatide is a dual agonist, engaging both GLP-1 and GIP receptors simultaneously. The additional GIP component provides peripheral adipose tissue signalling not achievable with GLP-1 alone — which is why SURMOUNT-1 demonstrated greater body weight reduction (22.5%) than STEP 1 (14.9%) at comparable timepoints.
What makes retatrutide different from tirzepatide?
Retatrutide adds glucagon receptor agonism to the GLP-1/GIP dual mechanism of tirzepatide — making it a triple agonist. The glucagon receptor component drives hepatic fat oxidation and brown adipose thermogenesis. Phase 2 data showed approximately 24.2% body weight reduction at 48 weeks (highest dose), compared to 22.5% with tirzepatide at 72 weeks — though direct comparison requires caution given different trial designs, durations, and populations.
How does AOD-9604 differ from GLP-1 compounds mechanistically?
AOD-9604 operates entirely independently of the incretin system. It selectively activates beta-3 adrenergic receptors in adipose tissue — driving lipolysis at the fat cell level without affecting central appetite regulation, insulin secretion, or IGF-1. GLP-1 analogs work primarily via central mechanisms (appetite suppression, satiety signalling); AOD-9604 works peripherally (direct fat cell catabolism). The two mechanisms are non-overlapping and can be studied in parallel models.
Are GLP-1 compounds legal to purchase in the UK?
Semaglutide, tirzepatide, and retatrutide are prescription-only medications (POMs) under the Human Medicines Regulations 2012. They cannot legally be supplied for human consumption without a prescription. Pure Grade Labs supplies semaglutide, tirzepatide, and retatrutide strictly as research chemicals for in vitro laboratory use only, which is a legally distinct category from consumer supply for human consumption.
What is the body composition research evidence for AOD-9604?
The primary evidence for AOD-9604 in body composition contexts comes from the METAOD Phase IIb trial programme, which tested five doses (1–30mg daily) versus placebo over 12 weeks. The 1mg dose demonstrated statistically significant fat mass reduction versus placebo without lean tissue loss or IGF-1 elevation — confirming mechanistic selectivity. Higher doses showed no additional benefit beyond the 1mg ceiling effect.
Summary
The peptide research landscape in body composition spans two mechanistically distinct categories. GLP-1 receptor agonists — semaglutide, tirzepatide, and retatrutide — operate primarily through central appetite regulation and incretin pathway modulation, with clinical trial data documenting 14.9% to 24.2% body weight changes across large randomised controlled trials. Non-incretin metabolic compounds including AOD-9604 operate through peripheral beta-3 adrenergic activation in adipose tissue — directly at the fat cell level, independent of central mechanisms.
The progression from GLP-1 monoagonism (semaglutide) to dual GLP-1/GIP agonism (tirzepatide) to triple GLP-1/GIP/glucagon agonism (retatrutide) reflects a systematic effort to recruit additional metabolic pathways alongside the core GLP-1 mechanism. Each addition has corresponded to measurable improvements in trial outcomes. Whether further receptor combinations will continue this trend is the core question in next-generation metabolic peptide research.
All compounds reviewed in this article are available from Pure Grade Labs for research purposes only. GLP-1 analogs (semaglutide, tirzepatide, retatrutide) are prescription-only medications and are supplied strictly as research chemicals for in vitro laboratory use. Not for human consumption.
References
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989–1002. DOI: 10.1056/NEJMoa2032183
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205–216. DOI: 10.1056/NEJMoa2206038
- Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389, 514–526. DOI: 10.1056/NEJMoa2301972
- Drucker DJ. (2006). The Biology of Incretin Hormones. Cell Metabolism, 3(3), 153–165. DOI: 10.1016/j.cmet.2006.01.004
- Rubino D et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA, 325(14), 1414–1425. DOI: 10.1001/jama.2021.3224
Last Updated: May 2026